FibroBiologics, Inc. (NASDAQ:FBLG – Get Free Report)’s stock price traded up 16% during trading on Thursday . The company traded as high as $11.75 and last traded at $11.01. 78,924 shares were traded during mid-day trading, a decline of 24% from the average session volume of 104,478 shares. The stock had previously closed at $9.49.
FibroBiologics Stock Performance
The stock has a fifty day simple moving average of $11.42.
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Read More
- Five stocks we like better than FibroBiologics
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 4/15 – 4/19
- Best Stocks Under $5.00
- Comprehensive Analysis of PayPal Stock
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.